Recently Viewed
Clear All$1.26
$-1.84
(-59.35%)
As on 02-Dec-2025 16:29EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$9 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-7.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
--
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$2.7
EPS
$-4.1
Face value
--
Shares outstanding
6,827,352
CFO
$-98.16 Mln
EBITDA
$-103.07 Mln
Net Profit
$-150.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sonnet Biotherapeutics Holdings Inc (SONN)
| -13.7 | -74.9 | -61.2 | -51.0 | -81.0 | -81.6 | -73.3 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Sonnet Biotherapeutics Holdings Inc (SONN)
| -89.3 | -93.1 | -80.0 | -81.6 | -85.5 | -54.3 | -50.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of... single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. Read more
Founder, Chairman, CEO & President
Dr. Pankaj Mohan Ph.D.
Founder, Chairman, CEO & President
Dr. Pankaj Mohan Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sonnet Biotherapeutics Holdings Inc (SONN) is $1.26 (NASDAQ) as of 02-Dec-2025 16:29 EDT. Sonnet Biotherapeutics Holdings Inc (SONN) has given a return of -81.04% in the last 3 years.
Since, TTM earnings of Sonnet Biotherapeutics Holdings Inc (SONN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.13
|
1.68
|
|
2024
|
-0.58
|
-8.96
|
|
2023
|
-0.37
|
-30.80
|
|
2023
|
-0.03
|
-2.78
|
|
2022
|
--
|
--
|
The 52-week high and low of Sonnet Biotherapeutics Holdings Inc (SONN) are Rs 19.30 and Rs 1.08 as of 05-Apr-2026.
Sonnet Biotherapeutics Holdings Inc (SONN) has a market capitalisation of $ 9 Mln as on 02-Dec-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Sonnet Biotherapeutics Holdings Inc (SONN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.